Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.
All News
Article
NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences.
Article
JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f
Article
A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.
Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Article
UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.
Article
Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Article
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Article
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.
Article
The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988 lives) or by a fictional catastrophe of 15 Airbus 320 jetliners (150 passengers each) crashing daily.
Dr. John Cush
Tweet
Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ
Dr. John Cush
Tweet
Dr Stanley Cohen has written a nice review of VTE with JAK inhibitors, points out that little/no risk during developmental trials, is not the same as a low risk seen with long term use in real world patients (older, higher BMI, more activity) https://t.co/0utVMqHdf9
Dr. John Cush
Tweet
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission). https://t.co/R59tLy8WGx
Dr. John Cush
Tweet
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses.
https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q
Dr. John Cush
Tweet
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis
Read more:
https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA
Dr. John Cush
Tweet
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% confidence interval 0.77–1.43). https://t.co/KpOEeVAAxx
Dr. John Cush
Tweet
#BestACR20Tweets
RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.
Dr. John Cush
Tweet
Lung Cancer Survival With Autoimmune Disease--a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
Learn more below.
https://t.co/ItVhityI1B https://t.co/tyTKAtGY2O
Dr. John Cush
Tweet
Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f
Dr. John Cush
Tweet
#UTSW Rheum Grand Rounds on Sarcoidosis w/ Dr. HSIA - Joints are involved in 15% of pts. Lung sking and ocular involvement predominate https://t.co/G4iWm4pLmO
